Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst Jasper Hellweg maintains a 'Buy' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $825 to $920.
September 15, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research maintains a 'Buy' rating on Regeneron Pharmaceuticals and raises the price target from $825 to $920.
The raised price target by Argus Research indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100